South Korean venture capital companies turn their eyes to promising biotech firms overseas, looking for a vehicle to accelerate their investment goals.
KTB Network recently joined hands with three Chinese venture capital companies to invest a total of 36 billion won ($30.1 million) in the country’s biopharma company CARsgen Therapeutics. The biotech company is highly praised for its immune cell therapy platform. It is working on a new method to treat patients with glioblastoma and hepatocellular carcinoma with a goal to conduct a clinical trial next year.
Image: http://pulsenews.co.kr
